Fas/CD95 Deficiency in ApcMin/+ Mice Increases Intestinal Tumor Burden by Guillen-Ahlers, Hector et al.
Fas/CD95 Deficiency in Apc
Min/+ Mice Increases Intestinal
Tumor Burden
Hector Guillen-Ahlers
1,2, Mark A. Suckow
4, Francis J. Castellino
1,2,3, Victoria A. Ploplis
1,2,3*
1W. M. Keck Center for Transgene Research, University of Notre Dame, Notre Dame, Indiana, United States of America, 2Department of Chemistry and Biochemistry,
University of Notre Dame, Notre Dame, Indiana, United States of America, 3Walther Cancer Research Center, University of Notre Dame, Notre Dame, Indiana, United States
of America, 4Freimann Life Science Center, University of Notre Dame, Notre Dame, Indiana, United States of America
Abstract
Background: Fas, a member of the tumor necrosis family, is responsible for initiating the apoptotic pathway when bound to
its ligand, Fas-L. Defects in the Fas-mediated apoptotic pathway have been reported in colorectal cancer.
Methodology/Principal Findings: In the present study, a variant of the Apc
Min/+ mouse, a model for the human condition,
Familial Adenomatous Polyposis (FAP), was generated with an additional deficiency of Fas (Apc
Min/+/Fas
lpr) by cross-
breeding Apc
Min/+ mice with Fas deficient (Fas
lpr) mice. One of the main limitations of the Apc
Min/+ mouse model is that it
only develops benign polyps. However, Apc
Min/+/Fas
lpr mice presented with a dramatic increase in tumor burden relative to
Apc
Min/+ mice and invasive lesions at advanced ages. Proliferation and apoptosis markers revealed an increase in cellular
proliferation, but negligible changes in apoptosis, while p53 increased at early ages. Fas-L was lower in Apc
Min/+/Fas
lpr mice
relative to Apc
Min/+ cohorts, which resulted in enhanced inflammation.
Conclusions/Significance: This study demonstrated that imposition of a Fas deletion in an Apc
Min/+ background results in a
more aggressive phenotype of the Apc
Min/+ mouse model, with more rapid development of invasive intestinal tumors and a
decrease in Fas-L levels.
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Introduction
Apoptosis is a regulated process that eliminates individual cells
that are damaged or infected. There are several signals capable of
triggering apoptosis, of which the activation of Fas/CD95/Apo-1
receptor (Fas) by Fas ligand (Fas-L) is the most studied [1]. Most
information about the Fas pathway is based on the immune
system, where Fas is highly expressed in activated T and B cells,
thymocytes, and lung and liver cells [2]. Cloning of the Fas
receptor (lpr) [3] and the Fas-L (gld) [4] genes led to studies
involving their potential roles in the activation of the apoptotic
pathway by death receptors. From these studies, a potential
mechanism evolved in which interaction of Fas-L with Fas results
in a conformational change of the receptor resulting in the
assembly of the death-inducing signaling complex, which is able to
recruit and cleave procaspase-8 (reviewed in [5]).
During colon cancer, regulation of the Fas system facilitates
tumor development. Some studies have shown that resistance of
colon carcinoma cells to apoptosis can be attributed to the elevated
expression of Fas-associated phosphatase-1 [6], which inhibits Fas
signaling by binding to the cytoplasmic tail of Fas. Another factor
that may contribute to apoptosis resistance is incomplete Fas
surface expression, with appropriate Fas mRNA levels but
deficient posttranslational processing, attenuating its cell surface
expression and remaining inactivated [7]. Amplification of a decoy
receptor for Fas-L in lung and colon cancer has also been reported
[8]. A number of investigations have proposed a ‘‘Fas counterat-
tack’’, which is thought to be an anti-host tumor-derived response
[9], where lymphocyte proliferation is compromised by tumor cells
expressing Fas-L. This induces apoptosis in the lymphocytes,
sparing tumor cells due to another mechanism, i.e., low Fas
surface expression [10,11,12]. This notion however, remains
controversial, and has been refuted by some investigators [13] and
contradicted by other in vivo studies [14,15,16,17].
The adenomatous polyposis coli multiple intestinal neoplasia
(Apc
Min/+) mouse model presents phenotypes reminiscent of
Familial Adenomatous Polyposis (FAP) in humans [18,19].
Patients with FAP develop multiple adenomas in the large
intestine, which lead to the development of malignant adenocar-
cinomas. The relevance of the Apc
Min/+ mouse model is that most
colorectal cancers also show alterations in expression of the Apc
gene [20,21]. Apc is a gatekeeper that regulates the levels of b-
catenin [22], a transcription factor that has Matrix metalloproteinase-7
[23] among its target genes. In the current study, Apc
Min/+ mice
were crossed with Fas deficient (Fas
lpr) mice to generate Apc
Min/+/
Fas
lpr mice in order to study the effect of a disrupted Fas-mediated
apoptotic machinery on tumor development and progression. The
results are summarized herein.
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Mice and Tissue Processing
The animal protocols used in this study were approved by the
University of Notre Dame Institutional Animal Care and Use
Committee. Male Apc
Min/+ and Fas-deficient (Fas
lpr) mice (5 weeks
old) were purchased from Jackson Laboratories (Bar Harbor, ME).
All animals were fed a rodent chow diet. For these studies, Apc
Min/+
mice were crossed with Fas
lpr mice to generate Apc
Min/+/Fas
lpr/+
mice, which were then bred to generate Apc
Min/+/Fas
lpr mice. Male
Apc
Min/+ and Apc
Min/+/Fas
lpr mice (8, 12, 16, 20, and 30 weeks) in a
C57BL/6 background, were used for all analyses. Tumor counting
was performed under a dissecting microscope by investigators
blinded to the genotype. Intestines were opened longitudinally,
cleaned, Swiss-rolled, fixed with periodate-lysine-paraformalde-
hyde (PLP), and embedded in paraffin.
Blood Analysis
Blood extracted intravenously from individual mice was treated
with EDTA and an aliquot (50 ml) was applied to an automated
CBC analyzer (Hemavet HV950FS, Drew Scientific, Oxford, CT,
USA) in order to determine the number of leukocytes (lympho-
cytes, neutrophils, monocytes), erythrocytes (red blood cells,
hemoglobin and hematocrit), and thrombocytes (platelets).
Histochemistry and Immunohistochemistry
Serial sections of paraffin-embedded tissue were cut for
haematoxylin and eosin (H&E) staining and for immunostaining.
Active caspase-3 and Fas-L were identified utilizing polyclonal
rabbit-anti-human active caspase-3 and Fas-L antibodies (Abcam,
Cambridge, MA), followed by HRP-conjugated goat-anti-rabbit
IgG (Santa Cruz Biotechnology, Santa Cruz, CA). PCNA was
identified utilizing a monoclonal mouse-anti-human PCNA
antibody (BioGenex, San Ramon, CA) as the primary antibody,
followed by HRP-conjugated rabbit-anti-mouse IgG (Santa Cruz
Biotechnology). A mouse monoclonal-anti-mouse p53 antibody
(Abcam) was used to detect p53, followed by HRP-conjugated
rabbit-anti-mouse IgG (AbD Serotec, Oxford, UK). Total Akt and
phosphorylated Akt were identified utilizing polyclonal rabbit-anti-
mouse Akt and pAkt antibodies (Abcam and Cell Signaling,
Danvers, MA, respectively), followed by biotinylated swine-anti-
rabbit IgG (Dako, Carpinteria, CA) and HRP-conjugated
streptavidin (BioGenex). CD45 and Mac-3 were identified utilizing
a monoclonal rat-anti-mouse antibodies for CD45 and Mac-3
(Pharmingen, San Diego, CA), followed by a biotinylated rabbit-
anti-mouse IgG (Dako, Carpinteria, CA) and HRP conjugated
streptavidin (Jackson, West Grove, PA). Phosphorylated Foxo3a
was identified utilizing a polyclonal rabbit-anti-rat Foxo3a
(phosphor S253) antibody (Abcam), followed by HRP-conjugated
goat-anti-rabbit IgG (Santa Cruz Biotechnology). All stains were
then developed in 3, 39-diaminobenzidine (DAB) and a haema-
toxylin QS counterstain was applied (Vector Laboratories,
Burlington, CA).
Stain Quantification and Statistical Analysis
Immunohistochemical stains were quantified using Spectrum
Plus (Version 9.0.748.1518) and ImageScope software (Aperio
Technologies, Vista, CA). Slides were scanned and loaded into an
electronic database at 20X by ScanScope CS (Aperio Technol-
ogies). For each stain, algorithms were developed to analyze either
the percent positive stained area per tumor area (Fas-L, Akt and
pAkt) or the number of positive cells per tumor area (PCNA,
caspase-3, p53, CD45, Mac-3 and p-Foxo3a).
Scanned slides were viewed in ImageScope where regions were
drawn around each tumor and analyzed with Spectrum software,
using algorithms designed for each stain. Stains using percent
positive area were analyzed using color deconvolution algorithms.
Stains requiring the number of positive cells per tumor area were
analyzed using algorithms that separate color by optical density
and also separate cells by outer membrane size and roundness.
Cells that fit within the parameters set for desired cell size and
shape and stain were counted, as was the area of each tumor
region. The average number of cells per tumor area was then
determined.
Statistical Analysis
For survival studies, the data were analyzed using the Kaplan-
Meier treatment and the comparison of survival between both
genotypes was performed using the log-rank test with Prism 4
software (GraphPad Software, La Jolla, CA). The Student’s t-test
was used for comparison of single pairs.
Results
Fas Deletion in Apc
Min/+ Mice Increases the Size and
Number of Intestinal Adenomas
Based on preliminary transcriptional profiling results of human
colon cancer samples, where a strong downregulation of a FAS-
related receptor was observed (data not shown), along with
published reports of compromised Fas-mediated apoptosis in colon
cancer, Apc
Min/+/Fas
lpr mice were generated to determine the
effects of a Fas deficiency in the Apc
Min/+ mouse model. Intestines
harvested at various timepoints revealed that Apc
Min/+/Fas
lpr mice
developed dramatically more intestinal adenomas than Apc
Min/+
mice, increasing rapidly with time (p,0.00001 at 8 weeks,
p=0.0072 at 12 weeks, p=0.0012 at 16 weeks, p=0.00019 at
20 weeks and p,0.00001 at 30 wks, n=4–10 for Apc
Min/+/Fas
lpr
and 5–21 for Apc
Min/+/Fas
lpr), and reaching a plateau of slightly
more than 70 adenomas after 16 weeks of age (Fig. 1A). The
largest difference was observed at 20 weeks, where Apc
Min/+/Fas
lpr
mice had on average 87 intestinal adenomas per mouse compared
to 13 in the Apc
Min/+ mice. The Fas
lpr mice, alone, did not generate
any intestinal polyps. For most time points, Apc
Min/+mice had
slightly larger adenomas, reaching significance at 16 weeks
(p,0.05) (Fig. 1B). At 30 weeks however, adenomas from
Apc
Min/+/Fas
lpr mice were significantly larger than adenomas from
Apc
Min/+ mice (p,0.01). Unlike Apc
Min/+ mice, where the location
of adenomas is almost exclusively in the small intestine, Apc
Min/+/
Fas
lpr mice after 16 weeks presented with large adenomas in the
large intestine, additional to the ones located at the small intestine.
Although there was significant tumor burden in Apc
Min/+ mice, it was
much lower than in Apc
Min/+/Fas
lpr mice. Additionally, Apc
Min/+/
Fas
lpr mice had a significantly reduced survival rate relative to
Apc
Min/+ mice (Fig. 1C). The survival curves were compared using a
log-rank test showing a significantly lower survival (p,0.001) in
Apc
Min/+/Fas
lpr mice (n=35)comparedtoApc
Min/+mice (n=89). The
percent survival of Apc
Min/+/Fas
lpr mice strongly decreased between
25 and 30 weeks and reached 44% at 30 weeks. This is about 12
weeks earlier than that observed in Fas
lpr mice [24]. Furthermore,
unlike Apc
Min/+ mice, Apc
Min/+/Fas
lpr mice presented with invasive
lesions in all animals at 30 weeks (Fig. 2). The invasive lesions
are not to be confused with herniation, a common occurrence in
Apc
Min/+ mice. All specimens were analyzed by a veterinary
pathologist utilizing standardized guidelines [25]. The percentage
of invasive lesions ranged from 3.0 to 15.4% (Table 1). However,
metastasis to other organs was not detected.
Fas and ApcMin Mice
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Min/+/Fas
lpr Mice Show Increased
Proliferation
To determine if increased polyps in the Apc
Min/+/Fas
lpr mice
were due to an increase in cellular proliferation and/or a
decrease in apoptosis, cells positive for proliferating cell nuclear
antigen (PCNA) (Fig. 3) and caspase-3 (data not shown) were
determined by immunohistochemistry. Several (18–205) polyps
from at least 4 mice were used for each time point and genotype.
Apc
Min/+/Fas
lpr mice had significantly more PCNA+ cells per
tumor area than Apc
Min/+ mice at most time points (p=0.0014 at
8w e e k s ,p =0 . 0 0 3 8a t1 6w e e k s ,p ,0.0001 at 20 weeks and 30
weeks, n=24–205 tumors for Apc
Min/+/Fas
lpr and 18–58 tumors
for Apc
Min/+ in 4–5 mice per genotype) (Fig. 3). Apoptosis activity
was determined by measuring cleaved caspase-3 levels. Surpris-
ingly, Apc
Min/+/Fas
lpr did not show a significant change in caspase-
3+ cells per tumor area at any time point, when compared to
Apc
Min/+mice. As another marker of apoptosis, p53 was also
measured by immunohistochemistry. An increase in p53 levels
was observed in Apc
Min/+/Fas
lpr mice compared to Apc
Min/+mice
Figure 1. Tumor burden and survival. (A) Intestinal tumor
number, (B) tumor size, and (C) survival rate of Apc
Min/+ and Apc
Min/+/
Fas
lpr mice. Error bars in panels (A)a n d( B) represent standard error of
the mean.
doi:10.1371/journal.pone.0009070.g001
Figure 2. Invasive lesions. H&E stains of intestinal adenoma sections
of Apc
Min/+/Fas
lpr mice at 30 weeks. The panel on the top represents an
entire polyp with evidence of an invasive lesion, further magnified in
the lower panel. Invasive lesions were analyzed by a veterinary
pathologist and were not identified as areas of herniation, which is
common in Apc
Min/+ mice.
doi:10.1371/journal.pone.0009070.g002
Table 1. Percentage of invasive lesions in 30 week Apc
Min/+/
Fas
lpr mice.
Mouse
Invasive
lesions
Non-invasive
lesions
Percentage of
invasive lesions
AP266 1 32 3.00%
AP281 2 21 8.70%
AP285 2 26 7.10%
AP286 3 35 7.90%
AP287 4 22 15.40%
doi:10.1371/journal.pone.0009070.t001
Fas and ApcMin Mice
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weeks (p=0.0009), 12weeks (p=0.012), and 16 weeks (p,0.0001)
in Apc
Min/+/Fas
lpr mice compared to Apc
Min/+ mice (n=26–177
tumors for Apc
Min/+/Fas
lpr and 18–78 tumors for Apc
Min/+ in 4–5
mice per genotype). After 20 weeks, both genotypes had similar
levels of p53.
Fas-L Is Decreased in Apc
Min/+ Mice Lacking Fas
Another study has reported an increase in intestinal tumor-
igenesis once functional Fas-L is lost in Apc
Min/+ mice [17]. To
determine if, in our Fas-deficient model, the levels of Fas-L within
the adenomas were altered, immunostains of Fas-L were
performed on intestinal sections of Apc
Min/+ and Apc
Min/+/Fas
lpr
mice (Fig. 5). Adenomas from the Apc
Min/+/Fas
lpr mice had
significantly less Fas-L per tumor area than Apc
Min/+mice. This
observation was consistent for all time points (p=0.039 at 8 weeks,
p,0.0001 at 12, 16, 20 and 30 weeks, n=28–198 tumors for
Apc
Min/+/Fas
lpr and 17–93 tumors for Apc
Min/+ in 4–5 mice per
genotype).
Akt, Foxo3a, and Inflammatory Markers in Intestinal
Tumors from Apc
Min/+/Fas
lpr and Apc
Min/+ Mice
Fas-L, aside from triggering Fas dependent apoptosis, is
considered to be an inducer of inflammation. To analyze
inflammation within tumors, stains for CD45 and Mac-3 were
performed on the intestines of Apc
Min/+/Fas
lpr and Apc
Min/+ mice
Figure 3. Immunohistochemistry for PCNA in adenomas from Apc
Min/ /+ and Apc
Min/ /+/Fas
lpr mice. (A) PCNA immunostains comparing
Apc
Min/+/Fas
lpr to Apc
Min/+ mice at 8 and 20 weeks. (B) Quantitation of PCNA positive cells per tumor area at five different time points. Error bars
represent standard error of the mean.
doi:10.1371/journal.pone.0009070.g003
Fas and ApcMin Mice
PLoS ONE | www.plosone.org 4 February 2010 | Volume 5 | Issue 2 | e9070(Fig. 6A). At 30 weeks, there were fewer positive cells for CD45 in
tumors of Apc
Min/+ mice (617699 +cells/mm
2, n=17 in 4 mice)
than in Apc
Min/+/Fas
lpr mice (2006686 +cells/mm
2, n=133 in 5
mice) (p,0.0001) (Fig. 6B). Mac-3, an antigen present on
macrophages, had the same trend with lower levels in tumors of
Apc
Min/+ mice (6236166 +cells/mm
2, n=21 in 4 mice) than in
Apc
Min/+/Fas
lpr mice (58046175 +cells/mm
2, n=151 in 5 mice)
(p,0.0001).
In addition to PCNA, cell survival was further analyzed by
staining for total Akt and its activated phosphorylated form (p-Akt)
(Fig. 6A). The stains revealed a predictable trend in which tumors
from Apc
Min/+/Fas
lpr mice showed higher levels of Akt (63.8%67.6
n=199 in 5 mice, versus 40.6%64.1, n=21 in 4 mice) and pAkt
(53.0%610.8, n=186 in 5 mice, versus 13.7%62.0, n=28 in 5
mice) than Apc
Min/+ mice (p,0.0001) (Fig. 6B). Akt is reported to
decrease expression of Fas-L by phosphorylating and, therefore,
inhibiting Foxo3a, a member of the forkhead family of
transcription factors responsible for Fas-L expression [26,27]. In
accordance with those reports, levels of phosphorylated Foxo3a (p-
Foxo3a) were higher in the tumors of Apc
Min/+/Fas
lpr mice
(70386230 +cells/mm
2, n=139 in 4 mice) compared to the
tumors in Apc
Min/+ mice (55236398 +cells/mm
2, n=20 in 3 mice)
(p=0.017) (Fig. 6A,B).
Hematology Profile
Prior to perfusion, blood was collected from all animals for
hematological profiling. Measurements of leukocyte (neutrophils,
lymphocytes, and monocytes) levels revealed that the averages
remained within the normal ranges (data not shown).
Apc
Min/+/Fas
lpr mice, at most time points, were anemic as
determined by red blood cell counts, hemoglobin, and percent
hematocrit. However, Apc
Min/+ mice, as well as Fas
lpr mice were
also anemic. Platelets, in all cases, were within normal ranges (data
not shown).
Figure 4. Immunohistochemistry for p53 in adenomas from Apc
Min/ /+ and Apc
Min/ /+/Fas
lpr mice. (A) Immunostains for the apoptosis marker
p53 in Apc
Min/+/Fas
lpr mice and Apc
Min/+ mice at 8 and 20 weeks. (B) Quantitation of p53 positive cells per tumor area at five different time points.
Error bars represent standard error of the mean.
doi:10.1371/journal.pone.0009070.g004
Fas and ApcMin Mice
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This study demonstrated that Apc
Min/+ mice develop more
intestinal adenomas when Fas is absent. An increase in
proliferation (measured by PCNA) was evident, especially at later
time points where an increase in Akt and pAkt was also observed.
Additionally, there was a decrease in Fas-L in Apc
Min/+/Fas
lpr mice.
A significant increase in inflammation and Mac-3 was also
observed in tumors of Apc
Min/+/Fas
lpr mice.
In the present study it was observed that at all time points (8, 12,
16, 20 and 30 weeks), Apc
Min/+ mice developed substantially more
intestinal adenomas when Fas was eliminated. These adenomas
also proved to be more aggressive. Incidences of intestinal prolapse
were common in the Apc
Min/+/Fas
lpr mice, especially at the later
time points. Overall, the poor health of these animals was
evidenced by their diminished survival rate as they approached 30
weeks of age. These findings were not surprising and were in
accord with expectations from disruption of the apoptotic pathway
Figure 5. Immunohistochemistry for Fas-L in adenomas from Apc
Min/ /+ and Apc
Min/ /+/Fas
lpr mice. (A) Immunostains for Fas-L
comparing Apc
Min/+/Fas
lpr and Apc
Min/+ mice at 8 and 20 weeks. (B) Quantitation of Fas-L immunostains. Error bars represent standard error of
the mean.
doi:10.1371/journal.pone.0009070.g005
Fas and ApcMin Mice
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caspase-3 and p53, were unexpected. There were no differences in
activated caspase-3 levels, but an increase in p53 levels was
observed in Apc
Min/+/Fas
lpr mice compared to Apc
Min/+ mice.
Changes in cleaved caspase-3 were also absent in previous studies
using Apc
Min/+ mice lacking Fas-L [17]. On the other hand, p53,
also an apoptotic marker, was higher in tumors of Apc
Min/+/Fas
lpr
mice compared to Apc
Min/+mice at early time points. However, this
difference was attenuated at 30 weeks, when Akt and pAkt were
observed to be higher in Apc
Min/+/Fas
lpr mice compared to Apc
Min/+
mice. Akt is a protein kinase activated by a variety of growth
factors [29,30] that in turn triggers activation of several cancer-
relevant downstream effector molecules, resulting in an environ-
ment that promotes proliferation and cell survival [31]. It has
previously been reported that Akt is capable of downregulating
p53 through phosphorylation of Mdm2 that results in a
translocation to the nucleus [32,33]. The increase of p53 might
also be a compensatory mechanism for a lack of Fas pathway. The
interdependence between Fas and p53 pathways has been
demonstrated by others [34,35].
In accordance with reports indicating that Akt regulation in Fas-L
expression is due to phosphorylation and, therefore, cytoplasmic
retention of the forkhead transcription factor FKHRL1/Foxo3a
[26,27], intestinal adenomas of the Apc
Min/+/Fas
lpr mice at later time
points presented with fewer Fas-L than tumors found in the Apc
Min/+
mice. This observation indicates that in the Apc
Min/+ mouse model, a
Fas deficiency does not compromise tumor growth. On the
contrary, by disrupting the Fas machinery, these tumors developed
faster, and in greater numbers. These results are consistent with
previous reports highlighting the anti-tumor effects of Fas-L [14,36],
as well as with recent findings of increased tumor burden in Apc
Min/+
mice deficient for Fas-L [17]. However, there are a number of
studies that report opposite findings where Fas-L confers more rapid
tumor formation in murine melanoma cells [37]. Higher Fas-L
Figure 6. Inflammation in adenomas of Apc
Min/ /+ and Apc
Min/ /+/Fas
lpr mice. (A) Immunostains for Mac-3, CD45, p-Foxo3a, Akt and pAkt in
adenomas from Apc
Min/+ and Apc
Min/+/Fas
lpr mice at 30 weeks. (B) Quantitation of Mac-3, CD45, p-Foxo3a, Akt, and pAkt immunostains. Error bars
represent standard error of the mean.
doi:10.1371/journal.pone.0009070.g006
Fas and ApcMin Mice
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compared to the primary tumor [38]. Those findings might
represent a compensatory mechanism for a disrupted Fas-mediated
apoptotic pathway. Despite the general assumption that high levels
of Fas-L would induce inflammation within the tumors, in the
present study it was observed that Apc
Min/+/Fas
lpr mice, which had
f a rl o w e rl e v e l so fF a s - Lt h a nApc
Min/+ mice, showed an increase in
inflammation at 30 weeks of age. The mechanism behind the
increased level of inflammation in tumors of Apc
Min/+/Fas
lpr mice is
likely related to a balance between membrane Fas-L (mFas-L) and
soluble Fas-L (sFas-L) (Fig. 7). mFas-L is a well known inducer of
inflammation while sFas-L has the opposite effect [39]. Mmp7 is
capable of cleaving mFas-L to yield sFas-L [40]. The Apc
Min/+ mouse
model and colon cancer in general show elevated levels of matrilysin
[41,42]. Therefore, it is not unlikely to assume that in this context
the balance between mFas-L and sFas-L would favor its soluble
form and therefore a direct correlation between Fas-L and
inflammation levels would be expected, as was observed in the
present study. Fas-L expression is regulated by Foxo3a, a member of
the forkhead family of transcription factors. Akt has been reported to
decrease Fas-L expression by phosphorylation and therefore
inactivation of Foxo3a. In accord with this mechanism, Apc
Min/+/
Fas
lpr mice showed higher levels of Akt, p-Akt, and p-Foxo3a, and
lower levels of Fas-L.
A relationship between inflammation and cancer has been
identified in a number of studies, and it is widely accepted that
inflammation creates conditions that promote tumor development
(reviewed in [43]). Furthermore, Mac-3, an antigen present on
macrophages, was present at higher levels in tumors of Apc
Min/+/
Fas
lpr mice and their presence within tumors promoted tumor
growth, invasion, and metastasis [44,45].
The results of the present study correlate to those of Fingleton
et al. [17] with differences that are worthy of further consideration.
Fingleton et al. used 17 week Apc
Min/+ mice lacking Fas-L instead of
its receptor, Fas. Both studies detected high levels of Fas-L in
Apc
Min/+ mice. While deficiencies of either Fas or FasL resulted in
an increase in tumor burden, in the current study, the increases in
tumor number ranged from ,300%, at early time points, to over
500%, at 16 weeks, whereas Fingleton et al. observed an increase
nearly 100% at 17 weeks. These differences in tumor burden are
most likely associated with difference in the inflammatory response
observed in these studies. Fingleton et al. did not observe any
significant changes in macrophage or lymphocyte infiltration, but
did see a 3-fold decrease in neutrophils in Apc
Min/+ mice lacking
Fas-L. In contrast, the current study demonstrated an obvious
increase in the inflammatory response in Apc
Min/+/Fas
lpr mice. This
supports the premise that the role played by in inflammation is
more relevant in tumor development than it is in tumor evasion of
the immune system. The current study, however, suggests that in
intestinal adenomas, the balance between mFas-L and sFas-L
levels, resulting from Mmp7 proteolysis, may regulate the pro- or
anti-inflammatory properties of Fas-L.
Among the main objectives for generating the Apc
Min/+/Fas
lpr
mice was to determine if a more aggressive variant of the Apc
Min/+
mouse model would evolve. At 30 weeks of age, all of the Apc
Min/+/
Fas
lpr mice had invasive lesions, which was not observed in the
Apc
Min/+ mouse model. It is likely that invasive lesions arise, at least
in part, as a result of an increase in Akt and its active form, since
this kinase has been shown to be involved in tumor invasion and
metastasis [46,47,48].
In summary, this study demonstrated that an additional Fas
deficiency in Apc
Min/+ mice causes a dramatic increase in the
number of intestinal tumors. The increase in the incidence of
adenoma development and the invasiveness of these adenomas,
paralleling a decrease in Fas-L in these mice, does not support the
Fas counterattack notion in this model. The increase in Mac-3 and
CD45 suggests a tumor permissive environment caused by a Fas-L
modulated inflammation.
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Figure 7. Proposed model for the increase in tumor burden in absence of Fas/CD95 in Apc
Min/ /+ mice. p-Akt inactivates Foxo3a by
phosphorylation and p-Foxo3a is not able to translocate to the nucleus. Foxo3a is involved in the transcription of Fas-L. Fas-L forms a homotrimer
transmembrane complex with a cleavage site (black circles), that is recognized by Mmp7. Mmp7 cleavage of mFas-L yields sFas-L (grey rectangles).
The membrane and soluble forms of Fas-L have opposite effects on inflammation.
doi:10.1371/journal.pone.0009070.g007
Fas and ApcMin Mice
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